Bio-Rad Posts $458.6 Million Profit On Sartorius Gain, Yet Its Operations Lost $49.7 Million

Restructuring and a roughly $50 million impairment drove the operating loss, while adjusted margin widened to 12.8% and the 2026 outlook held.

Share
Bio-Rad Posts $458.6 Million Profit On Sartorius Gain, Yet Its Operations Lost $49.7 Million

Bio-Rad Laboratories, which makes instruments and test kits for life science research and clinical diagnostics, reported net income of $458.6 million for the third quarter, or $17.02 a diluted share, against a $341.9 million loss a year earlier. The profit came mostly from a change in the fair market value of its Sartorius AG investment, while the business itself lost $49.7 million from operations, the company said Wednesday.

A profit built on an investment

The company booked a $588.2 million gain from the change in fair market value of equity securities and a loan receivable, versus a $495.3 million loss in the third quarter of 2025. It said the Sartorius change substantially contributed to the bottom line.

Operations told a different story. Standard-accounting operating results swung to a $49.7 million loss, a negative 7.6% margin, from $65.3 million of operating income a year earlier. Restructuring charges of about $77 million and a non-cash impairment of about $50 million on purchased intangibles, tied to discontinued and reprioritized R&D programs, drove the drop, according to the earnings presentation. Gross margin fell to 50.1% from 52.6%.

Adjusted margins widen, sales turn up

Excluding those items, adjusted operating income rose to $83.7 million from $77.0 million, and the adjusted operating margin reached 12.8% from 11.8%. Adjusted earnings were $2.65 a diluted share, up from $2.26. Free cash flow was $65.2 million, down from $89.2 million.

Sales edged up 0.5% to $656.4 million, or 0.7% on a currency-neutral basis. Clinical Diagnostics, which sells test systems and kits to hospital and reference labs, rose 2.7% to $401.8 million, led by quality systems and diabetes products.

Life Science slipped 2.8% to $254.6 million, or 2.4% currency-neutral, on lower process chromatography sales and a weak academic research market. Droplet Digital PCR sales rose, with the instrument line up more than 20%, the presentation said.

CEO Norman Schwartz said the company "returned to currency-neutral revenue growth" and that progress "gives us confidence in our 2026 outlook."

Outlook unchanged, next stop UBS

Bio-Rad kept its 2026 forecast: adjusted currency-neutral revenue from a decline of about 3.0% to growth of about 0.5%, and an adjusted operating margin of about 10.0% to 12.0%.

CFO Roop Lakkaraju is scheduled to take part in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 10, at 8:00 a.m. Eastern, the company said.

Management discussed the results on a call at 5:00 p.m. Eastern on Wednesday, with the UBS appearance next.

Sources